{"id":23917,"date":"2021-10-21T11:17:11","date_gmt":"2021-10-21T15:17:11","guid":{"rendered":"https:\/\/avalere.com\/?p=23917"},"modified":"2023-06-14T16:27:32","modified_gmt":"2023-06-14T20:27:32","slug":"achieving-readiness-for-radioligand-therapy-in-the-us","status":"publish","type":"post","link":"https:\/\/advisory.avalerehealth.com\/webinars\/achieving-readiness-for-radioligand-therapy-in-the-us","title":{"rendered":"Achieving Readiness for Radioligand Therapy in the US"},"content":{"rendered":"

Radioligand <\/a>therapy<\/a>\u00a0is a highly targeted cancer therapy that finds cancer cells and delivers radiation directly to these cells. It is currently approved for use in certain types of neuroendocrine tumors and lymphoma, and is under investigation for metastatic prostate cancers and other cancers.<\/p>\n

With new applications of radioligand therapy on the horizon, we must consider how to reduce existing variation in access and also proactively plan for wider use in the future.<\/p>\n

To support the integration of radioligand therapy into US health systems,\u00a0The Health Policy Partnership<\/a>, in collaboration with an Expert Advisory Panel and support from Avalere Health<\/a>,<\/a> has developed a\u00a0policy action blueprint and accompanying situation analysis report. This virtual event will explore the evidence-based, consensus-driven policy recommendations to improve integration and system readiness for radioligand therapy, and provide a deeper look into the barriers to and opportunities for\u00a0greater use of the approach.<\/p>\n

Speakers will include:<\/h2>\n